Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.amjmed.2020.10.040 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The use of denosumab in osteoporosis - an update on efficacy and drug safety.
Expert Opin Drug Saf
September 2024
Mercy Health Osteoporosis and Bone Health Services, Cincinnati, OH, USA.
Introduction: Denosumab (Prolia) is a fully human monoclonal antibody against the receptor activator of the nuclear factor kappaB ligand. It is a potent antiresorptive agent that reduces osteoclastogenesis.
Areas Covered: Denosumab has been shown to improve bone mineral density and reduce the incidence of new fractures in postmenopausal women and men.
Hypocalcemia and Hypophosphatemia following Concurrent Denosumab Injection and Ferric Carboxymaltose Infusion in a Patient with Normal Renal Function.
Case Rep Endocrinol
February 2024
Department of Endocrinology & Diabetes, Alfred Hospital, Melbourne, Australia.
Hypocalcemia following denosumab administration is well described. Hypophosphatemia following an intravenous iron infusion is an increasingly recognized adverse effect. Intravenous iron preparations increase fibroblast growth factor 23 (FGF23) levels.
View Article and Find Full Text PDFEffects of PTH glandular and external dosing patterns on bone cell activity using a two-state receptor model-Implications for bone disease progression and treatment.
PLoS One
April 2023
Mechanical, Medical and Process Engineering, Queensland University of Technology, Brisbane, Queensland, Australia.
Temporal aspects of ligand specificity have been shown to play a significant role in the case of pulsatile hormone secretion, as exemplified by parathyroid hormone (PTH) binding to its receptor (PTH1R), a G-protein-coupled receptor expressed on surfaces of osteoblasts and osteocytes. The latter binding reaction regulates intracellular signalling and subsequently modulates skeletal homeostasis via bone remodelling. PTH glandular secretion patterns dictate bone cellular activity.
View Article and Find Full Text PDFSafety of denosumab in patients with chronic kidney disease.
Saudi J Kidney Dis Transpl
May 2022
Department of Renal Medicine, Royal Hospital, Muscat, Oman.
Chronic kidney disease (CKD) is associated with bone and mineral disturbances in the form of renal osteodystrophy. The American College of Rheumatology Guidelines for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis 2017 recommend against treatment with denosumab in adult patients who have received an organ transplant and who are continuing treatment with glucocorticoids due to lack of adequate safety data on infections in adults treated with multiple immunosuppressive agents. Therefore, this study was conducted to compare the safety of denosumab in patients with CKD, especially in a group of patients who received immunosuppressive medications, and to assess the rate of infections in such group in comparison to patients with normal renal function.
View Article and Find Full Text PDFGlucocorticoid-Induced Hypocalcemia in a Patient with Established Hypoparathyroidism.
Am J Med
May 2021
Department of Endocrinology, King's College Hospital NHS Foundation Trust, Denmark Hill, London, UK; Department of Obesity, Immunometabolism and Diabetes, School of Life Course Sciences, Kings College London, UK; Division of Translational and Experimental Medicine - Reproductive Health, Warwick Medical School, University of Warwick, Coventry, UK.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!